

EE380: Exploring the Impact of a Rare Disease (RD) Diagnosis on Work Productivity and Social Activity Impairment: A Systematic Literature Review (SLR)

SLR references with data relating to work productivity and social activity

Huntington's disease

1. Claassen DO, DeCourcy J, Mellor J, Johnston C, Iyer RG. Impact of Chorea on Self-care Activity, Employment, and Health-care Resource Use in Patients with Huntington's Disease. *J Health Econ Outcomes Res.* 2021 Jun 21;8(1):99-105. doi: 10.36469/001c.24620. PMID: 34183975; PMCID: PMC8216765.
2. Cohn-Hokke PE, van Swieten JC, Pijnenburg YAL, Tibben A, Meijers-Heijboer H, Kievit A. The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. *J Genet Couns.* 2018 Aug;27(4):947-954. doi: 10.1007/s10897-017-0195-3. Epub 2017 Dec 21. PMID: 29270849.
3. Goh AMY, You E, Perin S, Clay FJ, Loi S, Ellis K, Chong T, Ames D, Lautenschlager N. Predictors of Workplace Disability in a Premanifest Huntington's Disease Cohort. *J Neuropsychiatry Clin Neurosci.* 2018 Spring;30(2):115-121. doi: 10.1176/appi.neuropsych.17040086. Epub 2017 Nov 29. PMID: 29183234.
4. Goh AMY, You E, Perin S, Lautenschlager NT, Clay FJ, Loi SM, Chong T, Ames D, Chiu E, Ellis KA. Alcohol Use, Mental Health, and Functional Capacity as Predictors of Workplace Disability in a Cohort With Manifest Huntington's Disease. *J Neuropsychiatry Clin Neurosci.* 2020 Summer;32(3):235-243. doi: 10.1176/appi.neuropsych.19090199. Epub 2020 Feb 27. PMID: 32102602.
5. Harris KL, Mason SL, Barker RA. Exploring the predictors of financial impairment in Huntington's disease using the Enroll-HD dataset. *J Neurol.* 2022 Jul;269(7):3501-3510. doi: 10.1007/s00415-021-10929-4. Epub 2022 Feb 14. PMID: 35165768; PMCID: PMC9217841.
6. J. Ko, X. Lu, A. Exuzides, R. Fuller, J. Luo. Burden of Huntington's disease (HD) on loss of employment status and its association with disease stage [abstract]. *Mov Disord.* 2020; 35 (suppl 1). <https://www.mdsabstracts.org/abstract/burden-of-huntingtons-disease-hd-on-loss-of-employment-status-and-its-association-with-disease-stage/>.
7. Peball M, Heim B, Ellmerer P, Frank F, Busin N, Galffy M, Djamshidian A, Seppi K. Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis. *Mov Disord Clin Pract.* 2022 May 5;9(5):628-636. doi: 10.1002/mdc3.13459. PMID: 35844271; PMCID: PMC9274354.
8. Penziner E, Williams JK, Erwin C, Bombard Y, Wallis A, Beglinger LJ, Hayden MR, Paulsen JS. Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. *Am J Med Genet B Neuropsychiatr Genet.* 2008 Apr 5;147(3):320-5. doi: 10.1002/ajmg.b.30600. PMID: 17948904; PMCID: PMC3645880.
9. Reshef S, Furr Stimming E, Sung VW, Willock R, Ribalov R, Brighton S, Leo S. (2023). EE375 Work and Activity Impairment in Huntington Disease [abstract]. *Value in Health* 26(6): S128.
10. Rodriguez Santana I, Frank S, Doherty M, Willock R, Hamilton J, Hubberstey H, Stanley C, Vetter L, Winkelmann M, Dolmetsch RE, Li N, Ratsch S, Ali TM. Humanistic Burden of Huntington

Disease: Evidence From the Huntington Disease Burden of Illness Study. *Neurol Clin Pract*. 2022 Dec;12(6):e172-e180. doi: 10.1212/CPJ.0000000000200095. PMID: 36540140; PMCID: PMC9757103.

11. Rodriguez Santana I, Frank S, Hamilton J, Hubberstey H, Amesen A, Ruiz L, Willock R, Doherty M, Dolmetsch RE, Li N, Ratsch S, Ali TM. (2022). POSB349 Work Productivity and Activity Impairment of Huntington's Disease Patients By Disease Stage in the US and EU5: Evidence from the Huntington's Disease Burden of Illness Study (HDBOI) [abstract]. *Value in Health* 25(1): S228.
12. Watkins K, Purks J, Kumar A, Sokas RK, Heller H, Anderson KE. Huntington's Disease and Employment: The Relative Contributions of Cognitive and Motor Decline to the Decision to Leave Work. *J Huntingtons Dis*. 2018;7(4):367-377. doi: 10.3233/JHD-180296. PMID: 30198875.

Dystrophic Epidermolysis Bullosa

1. Angelis A, Mellerio JE, Kanavos P. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. *Orphanet J Rare Dis*. 2022 Sep 6;17(1):346. doi: 10.1186/s13023-022-02419-1. PMID: 36068590; PMCID: PMC9450448.
2. Fortuna G, Aria M, Cepeda-Valdes R, Garcia-Garcia SC, Moreno Trevino MG, Salas-Alanís JC. Role of dystrophic epidermolysis bullosa in anxiety, depression and self-esteem: A controlled cross-sectional study. *J Dermatol*. 2016 Jan;43(1):70-8. doi: 10.1111/1346-8138.13027. Epub 2015 Jul 16. PMID: 26183725.

Hereditary angioedema

1. Anderson J, Soteres D, Mellor J, Connolly H, Wynne-Cattanach K, Earl L, Schultz B, Juethner S. (2021). PO56 Physician and patient reported outcomes by hereditary angioedema type: data from a real-world study [abstract]. *Annals of Allergy, Asthma & Immunology* 129(5):S27-S28.
2. Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, Boysen HB, Caballero T. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. *Orphanet J Rare Dis*. 2014 Jul 4;9:99. doi: 10.1186/1750-1172-9-99. PMID: 24996814; PMCID: PMC4105891.
3. Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, Jain G, Devercelli G. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. *Ann Allergy Asthma Immunol*. 2020 Jun;124(6):600-607. doi: 10.1016/j.anai.2020.02.018. Epub 2020 Mar 10. PMID: 32169514.
4. Blasco AJ, Lázaro P, Caballero T, Guilarte M. Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain. *Health Econ Rev*. 2013 Feb 12;3(1):2. doi: 10.1186/2191-1991-3-2. PMID: 23398817; PMCID: PMC3584739.
5. Bygum A, Aygören-Pürsün E, Beusterien K, Hautamaki E, Sisic Z, Wait S, Boysen HB, Caballero T. Burden of Illness in Hereditary Angioedema: A Conceptual Model. *Acta Derm Venereol*. 2015 Jul;95(6):706-10. doi: 10.2340/00015555-2014. PMID: 25394853.
6. Castaldo T, Selva C, Johnson P, Hunter AG, Tse J, Martinez A, Cortright A, Carroll H, Chen H, Lumry W. (2023). Comparison of Selected Health and Well Being Characteristics in Seniors with

Hereditary Angioedema (HAE) and a Non-HAE Patient Matched Cohort [abstract]. *Journal of Allergy and Clinical Immunology* 151(2): AB136.

7. Castaldo AJ, Jervelund C, Corcoran D, Boysen HB, Christiansen SC, Zuraw BL. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema. *Allergy Asthma Proc.* 2021 Mar 13;42(2):108-117. doi: 10.2500/aap.2021.42.200127. Epub 2021 Feb 13. PMID: 33581742; PMCID: PMC8133018.
8. Katelaris CH, Burton P, Perram F, Youssef S, Button PB, McCloud PI, Fenton K, Tognarini D. (2021). Living with HAE in Australia – the effect of prophylaxis on attack rate [abstract]. <https://aesirhealth.com.au/wp-content/uploads/2022/10/EAACI-2021.pdf>
9. Katelaris CH, Boicos K, Button PH, McCloud PI, Burton PK, Perram FA, Youssef S, Tognarini D. Living With Hereditary Angioedema in Australia: Findings From a National Observational Study Using Short Message Service to Monitor the Burden of Disease. *J Allergy Clin Immunol Pract.* 2023 Aug;11(8):2457-2467.e1. doi: 10.1016/j.jaip.2023.02.037. Epub 2023 Mar 12. PMID: 36918098.
10. Lo SH, Lloyd A, Elkhaila S, Sisic Z, van Nooten FE. Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. *Pharmacoecon Open.* 2022 Mar;6(2):231-239. doi: 10.1007/s41669-021-00302-6. Epub 2021 Sep 17. PMID: 34532843; PMCID: PMC8864034.
11. Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. *J Allergy Clin Immunol Pract.* 2018 Sep-Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31. PMID: 29391286.
12. Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H; on behalf of the COMPACT Investigators. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. *Orphanet J Rare Dis.* 2021 Feb 15;16(1):86. doi: 10.1186/s13023-020-01658-4. Erratum in: *Orphanet J Rare Dis.* 2021 Jul 28;16(1):329. PMID: 33588897; PMCID: PMC7885603.
13. Mendivil J, Murphy R, de la Cruz M, Janssen E, Boysen HB, Jain G, Aygören-Pürsün E, Hirji I, Devercelli G. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. *Orphanet J Rare Dis.* 2021 Feb 18;16(1):94. doi: 10.1186/s13023-021-01717-4. PMID: 33602292; PMCID: PMC7893968.
14. Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Mallbris L, Björkander J. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. *Allergy Asthma Proc.* 2014 Mar-Apr;35(2):185-90. doi: 10.2500/aap.2014.35.3738. Epub 2014 Jan 9. PMID: 24411585.
15. Nordenfelt P, Nilsson M, Lindfors A, Wahlgren CF, Björkander J. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. *Allergy Asthma Proc.* 2017 Nov 30;38(6):447-455. doi: 10.2500/aap.2017.38.4087. Epub 2017 Aug 30. PMID: 28855002.
16. Park K. (2023). 413 Evaluating the Impact of Acute Versus Prophylaxis Therapy in Hereditary Angioedema [abstract]. *Journal of Allergy and Clinical Immunology* 151(2): AB135.
17. Petraroli A, Squeglia V, Di Paola N, Barbarino A, Bova M, Spanò R, Marone G, Triggiani M. Home Therapy with Plasma-Derived C1 Inhibitor: A Strategy to Improve Clinical Outcomes and Costs in

Hereditary Angioedema. *Int Arch Allergy Immunol*. 2015;166(4):259-66. doi: 10.1159/000381341. Epub 2015 Apr 28. PMID: 25924832.

18. Spanò R, Di Paola N, Bova M, Barbarino A. Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema. *BMC Health Serv Res*. 2018 Jul 20;18(1):571. doi: 10.1186/s12913-018-3389-y. PMID: 30029666; PMCID: PMC6053759.

Transthyretin amyloidosis

1. Acaster S, Lo SH, Nestler-Parr S. A survey exploring caregiver burden and health-related quality of life in hereditary transthyretin amyloidosis. *Orphanet J Rare Dis*. 2023 Jan 26;18(1):17. doi: 10.1186/s13023-022-02601-5. PMID: 36698133; PMCID: PMC9878890.
2. Damy T, Adams D, Bridoux F, Gâteau G, Planté-Bordeneuve V, Ghiron Y, Farrugia A, Pelcot F, Taieb C, Labeyrie C, Jaccard A, Georgin-Lavialle S. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. *Amyloid*. 2022 Sep;29(3):165-174. doi: 10.1080/13506129.2022.2035354. Epub 2022 Feb 11. PMID: 35144512.
3. Martínez Valle F, Galan L, Buades J, Tarilonte P, Peral C, López-Ibáñez de Aldecoa A. (2022). POSC38 Study on the Management of Carriers in Hereditary Transthyretin Amyloidosis (EMPATIA): Economic and Healthcare Resource Utilization in Spain. *Value in Health* 25(1): S93-S94
4. Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, Lenderking WR. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers. *Neurol Ther*. 2018 Dec;7(2):349-364. doi: 10.1007/s40120-018-0106-z. Epub 2018 Aug 2. PMID: 30073497; PMCID: PMC6283802.

Alpha-1 antitrypsin deficiency

1. Borget I, Willemin MC, Pison C, Szeftel D, Bourkhis E, Moumane N, Matheron A, Lepage V. (2020). PRO137 Prevalence and Burden of ALPHA-1 Antitrypsin Deficiency in France: An Analysis from the French National Health Database (SNDS) [abstract]. *Value in Health* 23, S714.
2. Karl FM, Holle R, Bals R, Greulich T, Jörres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. *Respir Res*. 2017 Apr 17;18(1):60. doi: 10.1186/s12931-017-0543-8. PMID: 28416015; PMCID: PMC5392996.
3. Torres Redondo M, Campoa E, Ruano L, Sucena M. Health-Related Quality of Life in Patients With α 1 Antitrypsin Deficiency: A Cross Sectional Study. *Arch Bronconeumol*. 2017 Feb;53(2):49-54. doi: 10.1016/j.arbres.2016.05.024. Epub 2016 Jul 26. PMID: 27470706.